KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBIT: 2011-2024

Historic EBIT for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $54.4 million.

  • Esperion Therapeutics' EBIT rose 37.86% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 278.55%. This contributed to the annual value of $54.4 million for FY2024, which is 134.97% up from last year.
  • Latest data reveals that Esperion Therapeutics reported EBIT of $54.4 million as of FY2024, which was up 134.97% from -$155.6 million recorded in FY2023.
  • Esperion Therapeutics' EBIT's 5-year high stood at $54.4 million during FY2024, with a 5-year trough of -$226.7 million in FY2021.
  • Over the past 3 years, Esperion Therapeutics' median EBIT value was -$155.6 million (recorded in 2023), while the average stood at -$93.6 million.
  • In the last 5 years, Esperion Therapeutics' EBIT crashed by 86.77% in 2021 and then surged by 134.97% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' EBIT stood at -$121.4 million in 2020, then tumbled by 86.77% to -$226.7 million in 2021, then climbed by 20.83% to -$179.5 million in 2022, then climbed by 13.34% to -$155.6 million in 2023, then soared by 134.97% to $54.4 million in 2024.